DAMORA THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
DAMORA THERAPEUTICS, INC. (DMRA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$12.70 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-11-04
- DAMORA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$12.70M.
- DAMORA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was -$3.93M.
- DAMORA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-09-30 was -$14.36M.
- DAMORA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-12-31 was -$25.82M.
- DAMORA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$34.84M.
- DAMORA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$42.07M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2021-09-30 | -$12.70M 10-Q · filed 2021-11-04 | -$38.34M 10-Q · filed 2021-11-04 | ||
| 2020-12-31 | -$3.93M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$18.29M derived: sum of 2 quarters · filed 2021-11-04 | -$34.84M 10-K · filed 2021-03-29 | |
| 2020-09-30 | -$14.36M 10-Q · filed 2021-11-04 | -$30.91M 10-Q · filed 2021-11-04 | ||
| 2019-12-31 | -$25.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$31.33M derived: sum of 2 quarters · filed 2021-03-29 | -$42.07M 10-K · filed 2021-03-29 | |
| 2019-09-30 | -$5.51M 10-Q · filed 2020-12-11 | -$16.24M 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |